APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN)
APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: APADAZ; Generic name: BENZHYDROCODONE AND ACETAMINOPHEN; Manufacturer: Zevra Therapeutics, Inc..
| Brand name | APADAZ |
|---|---|
| Generic name | BENZHYDROCODONE AND ACETAMINOPHEN |
| Manufacturer | Zevra Therapeutics, Inc. |
| Used for | 1 INDICATIONS AND USAGE APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 ) ] reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. APADAZ should not be used for an extended period of time unless the p |
| Dosage | 2 DOSAGE AND ADMINISTRATION APADAZ should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. ( 2.1 ) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of APADAZ for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the subst |
| Warnings | WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF APADAZ Addiction, Abuse, and Misuse Because the use of APADAZ exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal res |
| Active ingredient(s) | ACETAMINOPHEN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0590d4e5-7107-4015-a6a8-deac14265aa2 |